Lyell Immunopharma (LYEL) Cash from Investing Activities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Cash from Investing Activities data on file, last reported at $17.4 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 74.98% year-over-year to $17.4 million; the trailing twelve-month figure through Mar 2026 stood at $2.0 million (down 98.82% YoY), and the FY2025 full-year result was $54.1 million, down 55.81% from the prior year.
• Cash from Investing Activities climbed to $17.4 million in Q1 2026, from -$31.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $152.9 million in Q2 2023 to a low of -$100.7 million in Q4 2023.
• A 5-year average of $21.6 million and a median of $22.0 million in 2024 frame the typical range for Cash from Investing Activities.
• Peak annual rise in Cash from Investing Activities reached 511.18% in 2023, while the deepest fall reached 315.85% in 2023.
• Tracing LYEL's Cash from Investing Activities over 5 years: stood at $46.6 million in 2022, then plunged by 315.85% to -$100.7 million in 2023, then soared by 153.14% to $53.5 million in 2024, then plunged by 158.62% to -$31.4 million in 2025, then surged by 155.41% to $17.4 million in 2026.
• Business Quant data shows LYEL's Cash from Investing Activities at $17.4 million in Q1 2026, -$31.4 million in Q4 2025, and $3.3 million in Q3 2025.